Infectious Diseases

Abrysvo is currently available in a kit containing a vial of lyophilized antigen component, a prefilled syringe containing diluent and a vial adapter.

Higher proportion of hospitalization events with critical outcomes seen for hospitalizations with at least 4 medical condition categories.

Government’s investment will pay for about 200 million tests to replenish the country’s stockpile.

No significant reduction seen in percent of patients with urgent care or emergency department visits or hospitalization.

Bacterial pneumonia treatment now available; FDA deny anaphylaxis treatment; flu vaccine efficacy results; flexible dosing for Talicia; change in the therapeutic equivalence for organ rejection drug generic. 

Molnupiravir and nirmatrelvir-ritonavir combination therapy should be considered for patients within 5 days of symptom onset.

Review and meta-analysis show improvements in functional exercise capacity vs standard of care.

New research suggests that mRNA COVID-19 vaccines can elevate PD-L1 expression levels in patients with advanced non-small cell lung cancer.

No variation in risk for PCC seen based on number of vaccinations, but previous infection linked to reduced PCC risk.

Xacduro is available as a kit containing a single dose vial of sulbactam 1g and 2 single-dose vials of durlobactam (0.5g in each vial).

By simplifying the dosing regimen, the Company hopes to improve patient adherence and treatment outcomes.

The FDA and CDC greenlight updated COVID-19; prescription drug for dry eye disease now available; head-to-head study compares Skyrizi to Stelara for Crohn disease; the REMS program has been updated for IBS treatment Lotronex; and the FDA cracks down on companies selling unnaproved eye products.

Incident hypertension, statin use higher with tenofovir alafenamide fumarate compared with tenofovir disoproxil fumarate.

New booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.

Interim analysis showed that the mRNA-1010 vaccine met all coprimary endpoints.

Shorter disease course with less mucosal disease seen on reinfection vs initial infection.

Interim data show vaccine effectiveness of 51.9% in 5 South American countries during their flu season.

The bivalent Pfizer-BioNTech and Moderna COVID-19 vaccines are no longer authorized for use in the United States.

Recurrent respiratory papillomatosis is caused primarily by HPV types 6 and 11.